volume 99, issue 4, P645-650 1997
DOI: 10.1542/peds.99.4.645
View full text
Committee on Fetus and Newborn

Abstract: ABSTRACT. Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth ( 35 weeks of gestation). RSV-IGIV administered monthly during the RSV season resulted in a 41% to 65% reduction in hospitalization rates in two clinical trials; however, RSV-IGIV is costly, and intravenous administration…

expand abstract